IsoRay Receives Final Regulatory Approval for GliaSite Brain Cancer Treatment

IsoRay, Inc. (NYSE: ISR) announced today it has received final approval from the State of Washington Department of Health to manufacture its GliaSite® radiation therapy system, a balloon catheter device used in the treatment of brain cancer.

In conjunction with the previously announced FDA clearance, the Washington State approval represents IsoRay's final regulatory hurdle to commence the sale of its GliaSite® brain cancer treatment in the United States. GliaSite® is a landmark technology that allows physicians to treat more brain cancer patients than ever before with internal radiation or brachytherapy.